Abstract:Background: Bone is naturally regenerable, with a high ability to repair itself. In massive segmental bone defect, bone cannot be repaired independently. Therefore, it is necessary to give a bone graft to promote the healing process. To date, autografts are the gold standard for bone grafts. However, some of the reported complications reported have led to auto-bone transplants being often disregarded. Both autografts or allografts also have some issues. Therefore, in an effort to develop alternative treatments for correcting bone defects and their consequences, bone tissue engineering (BTE) has gained popularity and is nowadays being researched as a potential alternative in bone defect management. There are three fundamental components in BTE combined: biomaterials (scaffolds), mesenchymal stem cells (MSCs), and growth factors. The combination of these components is believed to help the healing process of bone defects. Methods: This work was an animal study involving twenty Wistar strain Rattus norvegicus . They were divided into five groups: negative group (normal rats), positive group (rats with the bone defect without intervention), K-P1 group (rats with bone defect given SVF and porous carbonated- hydroxyapatite (HA)application), K-P2 group (rats with bone defect given SVF and nanocrystalline-HA application) and K-P3 (rats with bone defect giving SVF a bovine-HA application). After 30 days, the rats were sacrificed, the biomarkers osteocalcin and BMP-2 were evaluated. Biomarkers were quantified using ELISA. Results: Both osteocalcin and BMP-2 biomarker expressions were higher in intervention group (with SVF and scaffolds application) compared to the positive group (with no SVF and scaffolds treatment). The combination of SVF and bovine HA was reported significantly to have the highest osteocalcin and BMP levels when compared with other groups Conclusions: A combined application of SVF and scaffolds could aid the healing process in murine models with bone defect, marked by increasing levels of osteocalcin and BMP-2.

Bone Regeneration Using Bone Morphogenetic Proteins and Various Biomaterial Carriers

Strategies for delivering bone morphogenetic protein for bone healing

Biomaterials for the Delivery of Growth Factors and Other Therapeutic Agents in Tissue Engineering Approaches to Bone Regeneration

Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery)

Advances in the application of bone morphogenetic proteins and their derived peptides in bone defect repair

Bone morphogenetic proteins in orthopaedic trauma surgery

Recent Advances in Biomaterials for the Treatment of Bone Defects

BONE MORPHOGENETIC PROTEINS IN CLINICAL APPLICATIONS

Recent Trends in the Development of Bone Regenerative Biomaterials

BMP and TGFβ use and release in bone regeneration

Application of BMP in Bone Tissue Engineering

Advances in Growth Factor Delivery for Bone Tissue Engineering

Strategies for controlled delivery of growth factors and cells for bone regeneration

Advances in osteobiologic materials for bone substitutes

Use and efficacy of bone morphogenetic proteins in fracture healing

Bone regeneration: Biomaterials as local delivery systems with improved osteoinductive properties

Biomaterials, substitutes, and tissue engineering in bone repair: current and future concepts

Recent advances in gene therapy for bone tissue engineering

Bone Regeneration Using Gene-Activated Matrices

Bone tissue engineering application on fracture healing with bone defect as assessed through osteocalcin and bone morphogenetic protein-2 (BMP-2) biomarker examination: experimental study on murine models